ADAM6 levels significantly varied between CD22+/CD22− and CD45+/CD45−, while PRSS1 levels significantly varied between HLA-DR+/HLA-DR− ALL patients, suggesting their prognostic implications. This evidence concerns the gene PTPRC and acute lymphoblastic leukemia.